Ngā hua rapu - Asmussen, Jon Thor
- E whakaatu ana i te 1 - 6 hua o te 6
-
1
Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis mā Bjørnhart, Birgitte, Hansen, Karin Holmskov, Asmussen, Jon Thor, Jørgensen, Trine Lembrecht, Herrstedt, Jørn, Schytte, Tine
I whakaputaina 2022Text -
2
-
3
Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer mā Naghavi-Behzad, Mohammad, Oltmann, Hjalte Rasmus, Alamdari, Tural Asgharzadeh, Bülow, Jakob Lykke, Ljungstrøm, Lasse, Braad, Poul-Erik, Asmussen, Jon Thor, Vogsen, Marianne, Kodahl, Annette Raskov, Gerke, Oke, Hildebrandt, Malene Grubbe
I whakaputaina 2021Text -
4
FDG-PET/CT can rule out malignancy in patients with vocal cord palsy mā Thomassen, Anders, Nielsen, Anne Lerberg, Lauridsen, Jeppe Kiilerich, Blomberg, Björn Alexander, Hess, Søren, Petersen, Henrik, Johansen, Allan, Asmussen, Jon Thor, Sørensen, Jesper Roed, Johansen, Jørgen, Godballe, Christian, Høilund-Carlsen, Poul Flemming
I whakaputaina 2014Text -
5
Benefits and harms of implementing [(18)F]FDG-PET/CT for diagnosing recurrent breast cancer: a prospective clinical study mā Vogsen, Marianne, Jensen, Jeanette Dupont, Gerke, Oke, Jylling, Anne Marie Bak, Asmussen, Jon Thor, Christensen, Ivar Yannick, Braad, Poul-Erik, Thye-Rønn, Peter, Søe, Katrine Lydolph, Ewertz, Marianne, Hildebrandt, Malene Grubbe
I whakaputaina 2021Text -
6
Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT mā Naghavi-Behzad, Mohammad, Vogsen, Marianne, Vester, Rasmus Mølgård, Olsen, Maiken Madsen Bjerregaard, Oltmann, Hjalte, Braad, Poul-Erik, Asmussen, Jon Thor, Gerke, Oke, Vach, Werner, Kidholm, Kristian, Kodahl, Annette Raskov, Weber, Wolfgang, Hildebrandt, Malene Grubbe
I whakaputaina 2022Text